{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T23:29:56Z","timestamp":1771457396555,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13045-016-0240-y","type":"journal-article","created":{"date-parts":[[2016,2,13]],"date-time":"2016-02-13T04:07:23Z","timestamp":1455336443000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Allogeneic stem cell transplantation for X-linked agammaglobulinemia using reduced intensity conditioning as a model of the reconstitution of humoral immunity"],"prefix":"10.1186","volume":"9","author":[{"given":"Kazuhiro","family":"Ikegame","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohsuke","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoi","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Hoshino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Kanegane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Morio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuji","family":"Kaida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Soma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroya","family":"Tamaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyasu","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,2,13]]},"reference":[{"key":"240_CR1","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1542\/peds.9.6.722","volume":"9","author":"OC Bruton","year":"1952","unstructured":"Bruton OC. Agammaglobulinemia. Pediatrics. 1952;9:722\u20138.","journal-title":"Pediatrics"},{"key":"240_CR2","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0092-8674(93)90667-F","volume":"72","author":"S Tsukada","year":"1993","unstructured":"Tsukada S, Saffran DC, Rawlings DJ, Parolini O, Allen RC, Klisak I, et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell. 1993;72:279\u201390.","journal-title":"Cell"},{"key":"240_CR3","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/01.md.0000229482.27398.ad","volume":"85","author":"JA Winkelstein","year":"2006","unstructured":"Winkelstein JA, Marino MC, Lederman HM, Jones SM, Sullivan K, Burks AW, et al. X-linked agammaglobulinemia: report on a United States registry of 201 patients. Medicine (Baltimore). 2006;85:193\u2013202.","journal-title":"Medicine (Baltimore)"},{"key":"240_CR4","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1006\/clim.2002.5241","volume":"104","author":"A Plebani","year":"2002","unstructured":"Plebani A, Soresina A, Rondelli R, Amato GM, Azzari C, Cardinale F, et al. Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study. Clin Immunol. 2002;104:221\u201330.","journal-title":"Clin Immunol"},{"key":"240_CR5","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0022-3476(99)70246-5","volume":"134","author":"P Quartier","year":"1999","unstructured":"Quartier P, Debr\u00e9 M, De Blic J, de Sauverzac R, Sayegh N, Jabado N, et al. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. J Pediatr. 1999;134:589\u201396.","journal-title":"J Pediatr"},{"key":"240_CR6","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S1521-6616(03)00045-7","volume":"107","author":"V Howard","year":"2003","unstructured":"Howard V, Myers LA, Williams DA, Wheeler G, Turner EV, Cunningham JM, et al. Stem cell transplants for patients with X-linked agammaglobulinemia. Clin Immunol. 2003;107:98\u2013102.","journal-title":"Clin Immunol"},{"key":"240_CR7","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1002\/pbc.25554","volume":"62","author":"RF Abu-Arja","year":"2015","unstructured":"Abu-Arja RF, Chernin LR, Abusin G, Auletta J, Cabral L, Egler R, et al. Successful hematopoietic cell transplantation in a patient with X-linked agammaglobulinemia and acute myeloid leukemia. Pediatr Blood Cancer. 2015;62:1674\u20136.","journal-title":"Pediatr Blood Cancer"},{"key":"240_CR8","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(04)16628-2","volume":"364","author":"DA Jacobsohn","year":"2004","unstructured":"Jacobsohn DA, Duerst R, Tse W, Kletzel M. Reduced intensity haemopoietic stem-cell transplantation for treatment of non-malignant diseases in children. Lancet. 2004;364:156\u201362.","journal-title":"Lancet"},{"key":"240_CR9","first-page":"595","volume":"91","author":"T Futatani","year":"1998","unstructured":"Futatani T, Miyawaki T, Tsukada S, Hashimoto S, Kunikata T, Arai S, et al. Deficient expression of Bruton\u2019s tyrosine kinase in monocytes from X-linked agammaglobulinemia as evaluated by a flow cytometric analysis and its clinical application to carrier detection. Blood. 1998;91:595\u2013602.","journal-title":"Blood"},{"key":"240_CR10","first-page":"205","volume":"25","author":"N Nishida","year":"2015","unstructured":"Nishida N, Yang X, Takasaki I, Imai K, Kato K, Inoue Y, et al. Dysgammaglobulinemia associated with Glu349del, a hypomorphic XIAP mutation. J Investig Allergol Clin Immunol. 2015;25:205\u201313.","journal-title":"J Investig Allergol Clin Immunol"},{"key":"240_CR11","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jpeds.2009.05.026","volume":"155","author":"Y Morinishi","year":"2009","unstructured":"Morinishi Y, Imai K, Nakagawa N, Sato H, Horiuchi K, Ohtsuka Y, et al. Identification of severe combined immunodeficiency by T-cell receptor excision circles quantification using neonatal guthrie cards. J Pediatr. 2009;155:829\u201333.","journal-title":"J Pediatr"},{"key":"240_CR12","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/bmt.2014.123","volume":"49","author":"K Nakatani","year":"2014","unstructured":"Nakatani K, Imai K, Shigeno M, Sato H, Tezuka M, Okawa T, et al. Cord blood transplantation is associated with rapid B-cell neogenesis compared with BM transplantation. Bone Marrow Transplant. 2014;49:1155\u201361.","journal-title":"Bone Marrow Transplant"},{"key":"240_CR13","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1182\/blood.V88.2.561.bloodjournal882561","volume":"88","author":"S Hashimoto","year":"1996","unstructured":"Hashimoto S, Tsukada S, Matsushita M, Miyawaki T, Niida Y, Yachie A, et al. Identification of Bruton\u2019s tyrosine kinase (Btk) gene mutations and characterization of the derived proteins in 35 X-linked agammaglobulinemia families: a nationwide study of Btk deficiency in Japan. Blood. 1996;88:561\u201373.","journal-title":"Blood"},{"key":"240_CR14","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.bbmt.2006.06.007","volume":"12","author":"H Ogawa","year":"2006","unstructured":"Ogawa H, Ikegame K, Yoshihara S, Kawakami M, Fujioka T, Masuda T, et al. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning. Biol Blood Marrow Transplant. 2006;12:1073\u201384.","journal-title":"Biol Blood Marrow Transplant"},{"key":"240_CR15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13045-014-0098-9","volume":"8","author":"F Baron","year":"2015","unstructured":"Baron F, Zach\u00e9e P, Maertens J, Kerre T, Ory A, Seidel L, et al. Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2\u00a0Gy TBI or ATG plus 8\u00a0Gy TLI: a phase II randomized study from the Belgian Hematological Society. J Hematol Oncol. 2015;8:4.","journal-title":"J Hematol Oncol"},{"key":"240_CR16","doi-asserted-by":"crossref","first-page":"976","DOI":"10.3324\/haematol.2009.018267","volume":"95","author":"A Bacigalupo","year":"2010","unstructured":"Bacigalupo A, Socie' G, Lanino E, Prete A, Locatelli F, Locasciulli A, et al. Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA working party. Haematologica. 2010;95:976\u201382.","journal-title":"Haematologica"},{"key":"240_CR17","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/sj.bmt.1705240","volume":"37","author":"B Horn","year":"2006","unstructured":"Horn B, Baxter-Lowe LA, Englert L, McMillan A, Quinn M, Desantes K, et al. Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML. Bone Marrow Transplant. 2006;37:263\u20139.","journal-title":"Bone Marrow Transplant"},{"key":"240_CR18","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13045-015-0201-x","volume":"8","author":"Y Arai","year":"2015","unstructured":"Arai Y, Aoki K, Takeda J, Kondo T, Eto T, Ota S, et al. Clinical significance of high-dose cytarabine added to cyclophosphamide\/total-body irradiation in bone marrow or peripheral blood stem cell transplantation for myeloid malignancy. J Hematol Oncol. 2015;8:102.","journal-title":"J Hematol Oncol"},{"key":"240_CR19","first-page":"CD010280","volume":"7","author":"M Kharfan-Dabaja","year":"2014","unstructured":"Kharfan-Dabaja M, Mhaskar R, Reljic T, Pidala J, Perkins JB, Djulbegovic B, et al. Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation. Cochrane Database Syst Rev. 2014;7:CD010280.","journal-title":"Cochrane Database Syst Rev"},{"key":"240_CR20","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/bmt.2009.362","volume":"45","author":"JL Pi\u00f1ana","year":"2010","unstructured":"Pi\u00f1ana JL, Valc\u00e1rcel D, Fern\u00e1ndez-Avil\u00e9s F, Martino R, Rovira M, Barba P, et al. MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings. Bone Marrow Transplant. 2010;45:1449\u201356.","journal-title":"Bone Marrow Transplant"},{"key":"240_CR21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13045-014-0059-3","volume":"7","author":"YR Lai","year":"2014","unstructured":"Lai YR, Chen YH, Hu DM, Jiang M, Liu QF, Liu L, et al. Multicenter phase II study of a combination of cyclosporine a, methotrexate and mycophenolate mofetil for GVHD prophylaxis: results of the Chinese Bone Marrow Transplant Cooperative Group (CBMTCG). J Hematol Oncol. 2014;7:59.","journal-title":"J Hematol Oncol"},{"key":"240_CR22","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s12185-011-0931-7","volume":"94","author":"K Taniguchi","year":"2011","unstructured":"Taniguchi K, Okada M, Yoshihara S, Sawada A, Tokugawa T, Ishii S, et al. Strategy for bone marrow transplantation in eculizumab-treated paroxysmal nocturnal hemoglobinuria. Int J Hematol. 2011;94:403\u20137.","journal-title":"Int J Hematol"},{"key":"240_CR23","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.jaci.2014.11.029","volume":"135","author":"C Wehr","year":"2015","unstructured":"Wehr C, Gennery AR, Lindemans C, Schulz A, Hoenig M, Marks R, et al. Multicenter experience in hematopoietic stem cell transplantation for serious complications of common variable immunodeficiency. J Allergy Clin Immunol. 2015;135:988\u201397.","journal-title":"J Allergy Clin Immunol"},{"key":"240_CR24","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.aller.2013.09.013","volume":"43","author":"H Abolhassani","year":"2015","unstructured":"Abolhassani H, Hirbod-Mobarakeh A, Shahinpour S, Panahi M, Mohammadinejad P, Mirminachi B, et al. Mortality and morbidity in patients with X-linked agammaglobulinaemia. Allergol Immunopathol (Madr). 2015;43:62\u20136.","journal-title":"Allergol Immunopathol (Madr)"},{"key":"240_CR25","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/ejh.12524","volume":"95","author":"P Roll","year":"2015","unstructured":"Roll P, Muhammad K, Stuhler G, Grigoleit U, Einsele H, Tony HP. Effect of ATG-F on B-cell reconstitution after hematopoietic stem cell transplantation. Eur J Haematol. 2015;95:514\u201323.","journal-title":"Eur J Haematol"},{"key":"240_CR26","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1016\/S2352-3026(15)00045-9","volume":"2","author":"R Admiraal","year":"2015","unstructured":"Admiraal R, van Kesteren C, Jol-van der Zijde CM, Lankester AC, Bierings MB, Egberts TC, et al. Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis. Lancet Haematol. 2015;2:e194\u2013203.","journal-title":"Lancet Haematol"},{"key":"240_CR27","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s12185-013-1350-8","volume":"98","author":"H Fu","year":"2013","unstructured":"Fu H, Xu L, Liu D, Zhang X, Liu K, Chen H, et al. Late-onset hemorrhagic cystitis after haploidentical hematopoietic stem cell transplantation in patients with advanced leukemia: differences in ATG dosage are key. Int J Hematol. 2013;98:89\u201395.","journal-title":"Int J Hematol"},{"key":"240_CR28","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s12185-014-1542-x","volume":"99","author":"K Kaida","year":"2014","unstructured":"Kaida K, Ikegame K, Ikemoto J, Murata R, Irie R, Yoshihara S, et al. Soluble interleukin-2 receptor level on day 7 as a predictor of graft-versus-host disease after HLA-haploidentical stem cell transplantation using reduced-intensity conditioning. Int J Hematol. 2014;99:463\u201370.","journal-title":"Int J Hematol"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-016-0240-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T02:11:04Z","timestamp":1654308664000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jhoonline.org\/content\/9\/1\/9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,13]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["240"],"URL":"https:\/\/doi.org\/10.1186\/s13045-016-0240-y","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,13]]},"article-number":"9"}}